STOCK TITAN

NovelStem flags going-concern doubt with $22.7K cash

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

NovelStem International Corp. (NSTM) reported a net loss of $225,105 for the nine months ended September 30, 2026, compared with net income of $2,469,177 a year earlier. The 2025 result included a $1,171,760 gain on disposal of an equity-method investment and $1,697,024 in relief-of-indebtedness income. NSTM has no operating revenue and recorded $72,455 in general and administrative expenses.

At September 30, 2026, cash was $22,704 and current liabilities were $2,148,577; operating activities used $205,877 in cash during the nine-month period. On March 13, 2026, NSTM received $250,000 for 2,450,980 common shares. The company says it needs additional funds to continue operations over the next 12 months and that its circumstances raise substantial doubt about its ability to continue as a going concern. Management is pursuing financing and monetization of rights to NewStem technology, but says there is no assurance of sufficient financing or recovered value.

NSTM concluded its disclosure controls and internal control over financial reporting were ineffective as of September 30, 2026, citing a material weakness tied to insufficient resources for segregation of duties in transaction processing and financial reporting.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

3 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • None.

Negative

  • Major pointNine-month results shifted from $2,469,177 income in 2025 to a $225,105 loss in 2026.
  • Major point. Forward-looking: it has not happened yet and may not happen.Funding needed for operations over the next 12 months; substantial doubt remains.
  • Major pointIneffective controls at September 30, 2026 reflected a segregation-of-duties weakness.

Filing Explained

As of November 16, debt-to-equity talks remained negotiations; September 30 notes payable were $2,033,359, and any share-issuing conversion would dilute existing holders.

NovelStem says it is negotiating with all debt holders to convert debt into equity, but reports negotiations rather than a completed conversion; issuing additional shares would reduce existing holders’ percentage ownership.

At September 30, 2026, notes payable totaled $2,033,359 and were classified as current; the filing says these amounts are due within one year, with stated maturities including December 31, 2026 and March 30, 2027.

A separate convertible-debt balance was $128,029, including accrued interest, and its terms permit conversion at $0.13 per share.

Two unrelated-party notes also allow holders, in a future capital raise, to tender the notes at 133% of amounts owed for securities; August 2026 waivers addressed earlier transactions while leaving future-raise terms subject to a notice and election procedure.

Net loss $225,105 Nine months ended September 30, 2026
Net income $2,469,177 Nine months ended September 30, 2025
Cash $22,704 As of September 30, 2026
Current liabilities $2,148,577 As of September 30, 2026
Net cash used in operating activities $205,877 Nine months ended September 30, 2026
Common stock proceeds $250,000 Received March 13, 2026, for a private common-stock issuance
Common shares issued 2,450,980 shares Issued for $250,000 on March 13, 2026
Potential license monetization proceeds Up to $3,750,000 Under an agreement tied to monetization of NewStem licenses and related intangible assets
going concern financial
"ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
material weakness regulatory
"there is a material weakness in the design of our internal control"
A material weakness is a significant flaw in the systems and checks a company uses to ensure its financial reports are accurate, meaning errors or fraud could happen and not be caught. For investors it matters because it raises the risk that reported results are unreliable—similar to finding a hole in a ship’s hull—potentially leading to corrected financials, regulatory action, reduced trust, and negative effects on stock value and borrowing costs.
equity method financial
"accounted for under the equity method"
An equity method investment is an accounting approach used when a company owns enough of another business to influence its decisions but not control it (commonly around 20–50% ownership). Instead of counting only dividends, the investor records its share of the other company’s profits and losses on its own income statement and adjusts the investment’s value on the balance sheet—like tracking a friend’s joint project by noting your share of their gains or setbacks. For investors, this matters because it can significantly affect reported earnings, asset values, and the apparent strength of a company’s financial results.
convertible debt financial
"Convertible debt, including accrued interest"
A convertible debt is a loan a company takes that gives the lender the option to swap the owed money for a set number of the company’s shares instead of getting cash back. It matters to investors because it can change who owns the company and how much their shares are worth: if lenders convert, existing shareholders can be diluted, but conversion can also signal confidence and reduce a company’s cash pressure — like getting a coupon that can be redeemed for store ownership rather than a refund.
valuation allowance financial
"full valuation allowance against its net deferred tax assets"
A valuation allowance is a reserve set aside to reduce the value of certain assets on a company's financial records when there is uncertainty about whether they will generate the expected benefits. It acts like a caution sign, indicating that some assets might not be fully recoverable or worth their recorded amount. This matters to investors because it provides a more realistic picture of a company's financial health and potential risks.
nonrecourse litigation funding agreement financial
"entered into a nonrecourse litigation funding agreement"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was NSTM's net loss for the first nine months of 2026?

NovelStem reported a net loss of $225,105 for the nine months ended September 30, 2026, compared with net income of $2,469,177 in 2025. The 2025 total included a $1,171,760 gain on disposal of an equity-method investment and $1,697,024 of relief-of-indebtedness income.

How much did NSTM raise from its March 2026 stock issuance?

NSTM received $250,000 for 2,450,980 common shares in a privately negotiated transaction on March 13, 2026, or $0.102 per share. The proceeds were used for working capital and general corporate purposes.

When do NSTM's debt obligations mature?

The notes to unrelated parties, the notes to Jan Loeb, Executive Chairman, and Jerry Wolasky, a shareholder and member of the Board, the bridge loan, and the convertible notes were extended to mature on March 30, 2027. The $336,000 shareholder note matures on December 31, 2026.

How much could NSTM receive from monetizing the NewStem licenses?

NovelStem has an agreement to receive up to $3,750,000 from monetization of the licenses and related intangible assets. The agreement provides for funds in the event of re-licensing or monetization of the licenses or related technology.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false --12-31 Q3 0000912544 http://fasb.org/us-gaap/2026#OtherTaxExpenseBenefit http://fasb.org/us-gaap/2026#OtherTaxExpenseBenefit http://fasb.org/us-gaap/2026#OtherTaxExpenseBenefit http://fasb.org/us-gaap/2026#OtherTaxExpenseBenefit 0000912544 2026-01-01 2026-09-30 0000912544 2026-11-16 0000912544 2026-09-30 0000912544 2025-12-31 0000912544 2025-01-01 2025-09-30 0000912544 2026-07-01 2026-09-30 0000912544 2025-07-01 2025-09-30 0000912544 us-gaap:CommonStockMember 2025-12-31 0000912544 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0000912544 us-gaap:RetainedEarningsMember 2025-12-31 0000912544 us-gaap:TreasuryStockCommonMember 2025-12-31 0000912544 us-gaap:CommonStockMember 2026-03-31 0000912544 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0000912544 us-gaap:RetainedEarningsMember 2026-03-31 0000912544 us-gaap:TreasuryStockCommonMember 2026-03-31 0000912544 2026-03-31 0000912544 us-gaap:CommonStockMember 2026-06-30 0000912544 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0000912544 us-gaap:RetainedEarningsMember 2026-06-30 0000912544 us-gaap:TreasuryStockCommonMember 2026-06-30 0000912544 2026-06-30 0000912544 us-gaap:CommonStockMember 2024-12-31 0000912544 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000912544 us-gaap:RetainedEarningsMember 2024-12-31 0000912544 us-gaap:TreasuryStockCommonMember 2024-12-31 0000912544 2024-12-31 0000912544 us-gaap:CommonStockMember 2025-03-31 0000912544 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000912544 us-gaap:RetainedEarningsMember 2025-03-31 0000912544 us-gaap:TreasuryStockCommonMember 2025-03-31 0000912544 2025-03-31 0000912544 us-gaap:CommonStockMember 2025-06-30 0000912544 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0000912544 us-gaap:RetainedEarningsMember 2025-06-30 0000912544 us-gaap:TreasuryStockCommonMember 2025-06-30 0000912544 2025-06-30 0000912544 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0000912544 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0000912544 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0000912544 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-03-31 0000912544 2026-01-01 2026-03-31 0000912544 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0000912544 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0000912544 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0000912544 us-gaap:TreasuryStockCommonMember 2026-04-01 2026-06-30 0000912544 2026-04-01 2026-06-30 0000912544 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0000912544 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0000912544 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0000912544 us-gaap:TreasuryStockCommonMember 2026-07-01 2026-09-30 0000912544 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000912544 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000912544 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000912544 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0000912544 2025-01-01 2025-03-31 0000912544 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0000912544 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0000912544 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0000912544 us-gaap:TreasuryStockCommonMember 2025-04-01 2025-06-30 0000912544 2025-04-01 2025-06-30 0000912544 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0000912544 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0000912544 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0000912544 us-gaap:TreasuryStockCommonMember 2025-07-01 2025-09-30 0000912544 us-gaap:CommonStockMember 2026-09-30 0000912544 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0000912544 us-gaap:RetainedEarningsMember 2026-09-30 0000912544 us-gaap:TreasuryStockCommonMember 2026-09-30 0000912544 us-gaap:CommonStockMember 2025-09-30 0000912544 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0000912544 us-gaap:RetainedEarningsMember 2025-09-30 0000912544 us-gaap:TreasuryStockCommonMember 2025-09-30 0000912544 2025-09-30 0000912544 NSTM:NewStemLtdMember 2026-09-30 0000912544 NSTM:NetCoPartnersMember 2026-09-30 0000912544 2018-09-30 0000912544 NSTM:ShareholdersAndDirectorsMember 2026-09-30 0000912544 NSTM:ShareholdersAndDirectorsMember 2026-01-01 2026-09-30 0000912544 2023-12-31 0000912544 2024-04-30 0000912544 NSTM:JanLoebMember us-gaap:BridgeLoanMember 2026-09-30 0000912544 NSTM:JanLoebMember us-gaap:BridgeLoanMember 2025-12-31 0000912544 us-gaap:CommonStockMember 2026-03-13 2026-03-13 0000912544 NSTM:NetCoPartnersMember 2025-05-09 0000912544 us-gaap:ConvertibleDebtMember 2026-01-01 2026-09-30 0000912544 us-gaap:ConvertibleDebtMember 2025-01-01 2025-09-30 0000912544 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-09-30 0000912544 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-30 0000912544 us-gaap:ConvertibleDebtMember 2026-07-01 2026-09-30 0000912544 us-gaap:ConvertibleDebtMember 2025-07-01 2025-09-30 0000912544 us-gaap:EmployeeStockOptionMember 2026-07-01 2026-09-30 0000912544 us-gaap:EmployeeStockOptionMember 2025-07-01 2025-09-30 0000912544 NSTM:NewStemLtdMember 2025-08-31 0000912544 NSTM:NewStemLtdMember 2025-08-14 2025-08-14 0000912544 NSTM:NetCoPartnersMember 2025-05-31 0000912544 NSTM:NetCoPartnersMember 2025-05-09 2025-05-09 0000912544 NSTM:NetCoPartnersMember 2026-01-01 2026-09-30 0000912544 NSTM:NetCoPartnersMember 2025-12-31 0000912544 NSTM:NetCoPartnersMember 2024-12-31 0000912544 NSTM:NetCoPartnersMember 2025-01-01 2025-12-31 0000912544 NSTM:NetCoPartnersMember 2026-09-30 0000912544 NSTM:NetCoPartnersMember 2025-01-01 2025-09-30 0000912544 NSTM:NetCoPartnersMember 2026-07-01 2026-09-30 0000912544 NSTM:NetCoPartnersMember 2025-07-01 2025-09-30 0000912544 NSTM:HewlettFundAIGHInvestmentPartnersLLCMember 2023-12-31 0000912544 NSTM:HewlettFundAIGHInvestmentPartnersLLCMember 2023-12-31 0000912544 NSTM:HewlettFundAIGHInvestmentPartnersLLCMember 2023-12-01 2023-12-31 0000912544 2026-03-13 2026-03-13 0000912544 2026-03-13 0000912544 NSTM:HewlettFundAIGHInvestmentPartnersLLCMember 2026-01-01 2026-09-30 0000912544 NSTM:HewlettFundAIGHInvestmentPartnersLLCMember 2025-01-01 2025-09-30 0000912544 NSTM:HewlettFundAIGHInvestmentPartnersLLCMember 2026-07-01 2026-09-30 0000912544 NSTM:HewlettFundAIGHInvestmentPartnersLLCMember 2025-07-01 2025-09-30 0000912544 NSTM:TwoIndividualsMember NSTM:NoteAgreementMember 2022-05-31 0000912544 NSTM:TwoIndividualsMember NSTM:NoteAgreementMember 2024-03-31 0000912544 NSTM:TwoIndividualsMember NSTM:NoteAgreementMember 2024-08-31 0000912544 NSTM:TwoIndividualsMember NSTM:NoteAgreementMember 2026-09-30 0000912544 NSTM:TwoIndividualsMember NSTM:NoteAgreementMember 2026-01-01 2026-09-30 0000912544 NSTM:TwoIndividualsMember NSTM:NoteAgreementMember 2025-01-01 2025-09-30 0000912544 NSTM:TwoIndividualsMember NSTM:NoteAgreementMember 2026-07-01 2026-09-30 0000912544 NSTM:TwoIndividualsMember NSTM:NoteAgreementMember 2025-07-01 2025-09-30 0000912544 NSTM:ShareholderMember 2026-09-30 0000912544 2025-05-01 2025-05-31 0000912544 2025-10-01 2025-10-01 0000912544 NSTM:OmniBridgewayFund4Invt3LPMember 2022-02-11 2022-02-11 0000912544 NSTM:OmniBridgewayFund4Invt3LPMember 2023-07-31 0000912544 NSTM:OmniBridgewayFund4Invt3LPMember 2023-07-01 2023-07-31 0000912544 NSTM:OmniBridgewayFund4Invt3LPMember 2025-01-10 0000912544 NSTM:OmniBridgewayFund4Invt3LPMember 2025-01-01 2025-09-30 0000912544 NSTM:NetCoPartnersMember 2025-05-09 2025-05-09 0000912544 NSTM:JanLoebMember us-gaap:BridgeLoanMember 2025-02-01 2025-02-28 0000912544 NSTM:JanLoebMember us-gaap:BridgeLoanMember 2026-01-01 2026-09-30 0000912544 NSTM:JanLoebMember 2026-09-30 0000912544 NSTM:JanLoebMember us-gaap:BridgeLoanMember 2026-07-01 2026-09-30 0000912544 NSTM:JanLoebMember 2026-01-01 2026-09-30 0000912544 NSTM:JanLoebMember us-gaap:BridgeLoanMember 2025-01-01 2025-12-31 0000912544 NSTM:JanLoebMember us-gaap:BridgeLoanMember 2025-01-01 2025-09-30 0000912544 NSTM:JanLoebMember us-gaap:BridgeLoanMember 2025-07-01 2025-09-30 0000912544 us-gaap:NonrelatedPartyMember NSTM:ConvertibleDebtAgreementsMember 2024-04-01 2024-04-30 0000912544 us-gaap:NonrelatedPartyMember NSTM:ConvertibleDebtAgreementsMember 2024-04-30 0000912544 us-gaap:NonrelatedPartyMember NSTM:ConvertibleDebtAgreementsMember 2026-08-01 2026-08-31 0000912544 us-gaap:NonrelatedPartyMember NSTM:ConvertibleDebtAgreementsMember 2026-08-31 0000912544 us-gaap:NonrelatedPartyMember NSTM:ConvertibleDebtAgreementsMember 2026-01-01 2026-09-30 0000912544 us-gaap:NonrelatedPartyMember NSTM:ConvertibleDebtAgreementsMember 2025-01-01 2025-09-30 0000912544 us-gaap:NonrelatedPartyMember NSTM:ConvertibleDebtAgreementsMember 2026-07-01 2026-09-30 0000912544 us-gaap:NonrelatedPartyMember NSTM:ConvertibleDebtAgreementsMember 2025-07-01 2025-09-30 0000912544 NSTM:HewlettFundAndAIGHInvestmentPartnersLLCMember 2026-09-30 0000912544 NSTM:HewlettFundAndAIGHInvestmentPartnersLLCMember 2025-12-31 0000912544 NSTM:DirectorAndExecutiveChairmanMember us-gaap:RelatedPartyMember 2026-09-30 0000912544 NSTM:DirectorAndExecutiveChairmanMember us-gaap:RelatedPartyMember 2025-12-31 0000912544 us-gaap:RelatedPartyMember NSTM:ShareholderMember 2026-09-30 0000912544 us-gaap:RelatedPartyMember NSTM:ShareholderMember 2025-12-31 0000912544 us-gaap:RelatedPartyMember us-gaap:BridgeLoanMember 2026-09-30 0000912544 us-gaap:RelatedPartyMember us-gaap:BridgeLoanMember 2025-12-31 0000912544 us-gaap:RelatedPartyMember 2026-09-30 0000912544 us-gaap:RelatedPartyMember 2025-12-31 0000912544 us-gaap:ConvertibleDebtMember 2026-09-30 0000912544 us-gaap:ConvertibleDebtMember 2025-12-31 0000912544 us-gaap:CommonStockMember NSTM:AccreditedInvestorMember 2026-03-01 2026-03-31 0000912544 us-gaap:CommonStockMember NSTM:AccreditedInvestorMember 2026-03-31 0000912544 us-gaap:AdditionalPaidInCapitalMember NSTM:AccreditedInvestorMember 2026-03-01 2026-03-31 0000912544 NSTM:DirectorsAndInvestorsMember 2018-11-12 2018-11-12 0000912544 NSTM:DirectorsAndInvestorsMember 2026-01-01 2026-09-30 0000912544 NSTM:DirectorsAndInvestorsMember 2026-09-30 0000912544 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-09-30 0000912544 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-30 0000912544 us-gaap:EmployeeStockOptionMember 2025-07-01 2025-09-30 0000912544 us-gaap:EmployeeStockOptionMember 2026-07-01 2026-09-30 0000912544 us-gaap:EmployeeStockOptionMember us-gaap:CommonStockMember 2026-01-01 2026-09-30 0000912544 us-gaap:EmployeeStockOptionMember 2025-12-31 0000912544 us-gaap:EmployeeStockOptionMember 2026-09-30 0000912544 us-gaap:DomesticTaxJurisdictionFederalStateAndLocalMember 2026-07-01 2026-09-30 0000912544 us-gaap:DomesticTaxJurisdictionFederalStateAndLocalMember 2025-07-01 2025-09-30 0000912544 NSTM:DirectorsAndOfficersMember 2026-07-31 0000912544 NSTM:DirectorsAndOfficersMember NSTM:TenMonthlyInstallmentsMember 2026-07-31 0000912544 NSTM:DirectorsAndOfficersMember 2026-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _________________ to _________________

 

Commission file number: 001-14332

 

NOVELSTEM INTERNATIONAL CORP.

(Exact name of registrant as specified in its charter)

 

Florida   65-0385686

(State or other jurisdiction

of incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

7740 Cavern Lane Suite 100, Parkland FL   33067
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code (410) 598-9024  

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None        

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer  ☒ Smaller reporting company  ☒
  Emerging growth company  ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

Class   Outstanding at November 16, 2026
Common Stock, $0.01 par value per share   49,332,455

 

 

 

 
 

 

NOVELSTEM INTERNATIONAL CORP.

Quarterly Report on Form 10-Q

for the Quarterly Period Ended September 30, 2026

 

TABLE OF CONTENTS

 

  PAGE
   
Part I Financial Information  
   
Item 1. Unaudited Condensed Financial Statements:  
   
Unaudited Condensed Balance Sheets as of September 30, 2026 and December 31, 2025 3
   
Unaudited Condensed Statements of Operations for the nine and three months ended September 30, 2026 and 2025 4
   
Unaudited Condensed Statements of Changes in Shareholders’ Deficit for the three and nine months ended September 30, 2026 and 2025 5
   
Unaudited Condensed Statements of Cash Flows for the nine months ended September 30, 2026 and 2025 6
   
Notes to Unaudited Condensed Financial Statements 7
   
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 15
   
Item 3. Quantitative and Qualitative Disclosures About Market Risk 18
   
Item 4. Controls and Procedures 18
   
Part II Other Information  
   
Item 1. Legal Proceedings 19
   
Item 1A. Risk Factors 19
   
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 19
   
Item 3. Defaults Upon Senior Securities 19
   
Item 4. Mine Safety Disclosures 19
   
Item 5. Other Information 19
   
Item 6. Exhibits 19
   
Signatures 20

 

2
 

 

PART I

 

ITEM 1. UNAUDITED CONDENSED FINANCIAL STATEMENTS

 

NOVELSTEM INTERNATIONAL CORP.

CONDENSED BALANCE SHEETS

 

   September 30,   December 31, 
   As of 
   September 30,   December 31, 
   2026   2025 
   (Unaudited)     
         
ASSETS          
Current assets:          
Cash  $22,704   $333 
Prepaid expenses   9,113    15,453 
Total current assets   31,817    15,786 
Total assets  $31,817   $15,786 
           
LIABILITIES AND SHAREHOLDERS’ DEFICIT          
Current liabilities:          
Accounts payable  $77,545   $215,958 
Accrued expenses   37,673    37,673 
Notes payable, including accrued interest   347,196    317,734 
Notes payable related parties, including accrued interest   1,395,863    1,295,405 
Bridge loan payable, related party, including accrued interest   162,271    171,857 
Convertible debt, including accrued interest   128,029    118,814 
Total current liabilities   2,148,577    2,157,441 
Total liabilities   2,148,577    2,157,441 
Commitments and contingencies (See Note 7)        - 
Shareholders’ deficit:          
Common stock, $.01 par value, 100,000,000 shares authorized, 52,767,652 and 50,316,672 shares issued at September 30, 2026 and December 31, 2025, respectively, and 49,332,455 and 46,881,475 shares outstanding at September 30, 2026 and December 31, 2025, respectively   493,325    468,815 
Additional paid-in capital   291,795,745    291,570,255 
Accumulated deficit   (294,206,076)   (293,980,971)
Treasury stock, at cost, 3,435,197 shares at September 30, 2026 and December 31, 2025   (199,754)   (199,754)
Total shareholders’ deficit   (2,116,760)   (2,141,655)
Total liabilities and shareholders’ deficit  $31,817   $15,786 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

3
 

 

NOVELSTEM INTERNATIONAL CORP.

CONDENSED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   2026   2025   2026   2025 
   Nine Months Ended   Three Months Ended 
   September 30,   September 30, 
   2026   2025   2026   2025 
                 
Operating expenses:                    
General and administrative expenses   72,455    198,007    32,567    39,469 
Total operating expenses   72,455    198,007    32,567    39,469 
Loss from operations   (72,455)   (198,007)   (32,567)   (39,469)
Other (income) expenses:                    
Gain on disposal of equity method investment   -    (1,171,760)   -    - 
Relief of indebtedness income   -    (1,697,024)   -    - 
Interest expense   152,650    207,672    51,722    43,711 
Total other (income) expenses   152,650    (2,661,112)   51,722    43,711 
Income (loss) before income taxes   (225,105)   2,463,105    (84,289)   (83,180)
Provision for income tax   -    -    -    - 
Income (loss) before equity in net income (loss) of equity method investees   (225,105)   2,463,105    (84,289)   (83,180)
Equity in net income (loss) of equity method investees   -    640    -    300 
Impairment of equity method investee, NewStem   -    5,432    -    5,432 
Net income (loss)  $(225,105)  $2,469,177   $(84,289)  $(77,448)
                     
Basic and diluted net income (loss) per share:                    
Net income (loss) per share - basic  $(0.00)  $0.05   $(0.00)  $(0.00)
Weighted average number of shares outstanding - basic   48,695,021    46,881,475    49,332,455    46,881,475 
Net income (loss) per share - diluted  $(0.00)  $0.05   $(0.00)  $(0.00)
Weighted average number of shares outstanding - diluted   48,695,021    47,772,960    49,332,455    46,881,475 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

4
 

 

NOVELSTEM INTERNATIONAL CORP.

CONDENSED STATEMENTS OF SHAREHOLDERS’ DEFICIT

(UNAUDITED)

 

For the Three and Nine Months Ended September 30, 2026:

 

           Additional       Number of       Total 
   Number of   Common   Paid-In   Accumulated   Treasury   Treasury   Shareholders’ 
   Shares   Stock   Capital   Deficit   Shares   Stock   Deficit 
                             
Balance, January 1, 2026   46,881,475   $468,815   $291,570,255   $(293,980,971)   3,435,197   $(199,754)  $     (2,141,655)
Net loss   -    -    -    (55,021)   -    -    (55,021)
Stock issued for cash   2,450,980    24,510    225,490    -    -    -    250,000 
Balance, March 31, 2026   49,332,455   $493,325   $291,795,745   $(294,035,992)   3,435,197   $(199,754)  $(1,946,676)
Net loss   -    -    -    (85,795)   -    -    (85,795)
Balance, June 30, 2026   49,332,455   $493,325   $291,795,745   $(294,121,787)   3,435,197   $(199,754)  $(2,032,471)
Net loss   -    -    -    (84,289)   -    -    (84,289)
Balance, September 30, 2026   49,332,455   $493,325   $291,795,745   $(294,206,076)   3,435,197   $(199,754)  $(2,116,760)

 

For the Three and Nine Months Ended September 30, 2025:

 

           Additional       Number of       Total 
   Number of   Common   Paid-In   Accumulated   Treasury   Treasury   Shareholders’ 
   Shares   Stock   Capital   Deficit   Shares   Stock   Deficit 
                             
Balance, January 1, 2025   46,881,475   $468,815   $290,947,417   $(296,360,853)   3,435,197   $(199,754)  $     (5,144,375)
Net loss   -    -    -    (207,216)   -    -    (207,216)
Stock-based compensation   -    -    8,741    -    -    -    8,741 
Balance, March 31, 2025   46,881,475   $468,815   $290,956,158   $(296,568,069)   3,435,197   $(199,754)  $(5,342,850)
Net income   -    -    -    2,753,841    -    -    2,753,841 
Debt restructuring             614,000                   614,000 
Stock-based compensation   -    -    97    -    -    -    97 
Balance, June 30, 2025   46,881,475   $468,815   $291,570,255   $(293,814,228)   3,435,197   $(199,754)  $(1,974,912)
Net loss   -    -    -    (77,448)   -    -    (77,448)
Balance, September 30, 2025   46,881,475   $468,815   $291,570,255   $(293,891,676)   3,435,197   $(199,754)  $(2,052,360)

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

5
 

 

NOVELSTEM INTERNATIONAL CORP.

CONDENSED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

   2026   2025 
   Nine Months Ended 
   September 30, 
   2026   2025 
         
Cash flows from operating activities:          
Net income (loss)  $(225,105)  $2,469,177 
Accretion of discount on note payable   -    60,417 
Gain on disposal of equity method investment   -    (1,171,760)
Relief of indebtedness income   -    (1,697,024)
Accrued interest added to notes payable and convertible debt   151,301    145,638 
Noncash settlement of accounts payable   (67,500)   - 
Stock-based compensation   -    8,838 
Change in operating assets and liabilities:          
Accounts receivable, administrative fees   -    10,500 
Prepaid expenses   6,340    1,050 
Accounts payable   (70,913)   31,712 
Net cash used in operating activities   (205,877)   (141,452)
           
Cash flows from financing activities:          
Proceeds from issuances of short term notes payable  $28,248   $135,980 
Repayments of short term notes payable   (50,000)   - 
Proceeds from sale of common stock   250,000    - 
Net cash provided by financing activities   228,248    135,980 
           
Net change in cash   22,371    (5,472)
Cash at the beginning of the period   333    6,099 
Cash at the end of the period  $22,704   $627 
           
Supplemental cash flow information:          
Cash paid during the period for:          
Interest  $1,350   $1,616 
Income taxes  $-   $- 
Supplemental Non-Cash Investing and Financing Activities:          
Interest capitalized to notes payable  $-   $36,000 
Settlement of long term notes payable  $-   $2,997,025 
Settlement of derivative liability, net of interest  $-   $614,000 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

6
 

 

NOVELSTEM INTERNATIONAL CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 1—NATURE OF OPERATIONS

 

Description of Business

 

NovelStem International Corp. (“NovelStem” or the “Company”) is a holding company whose principal assets consisted of an approximate 31% equity interest in NewStem Ltd, an Israeli biotech company (“NewStem”) and its developed technology, and a 50% equity interest in NetCo Partners (“NetCo”). The interest in NetCo was sold in May 2025 in a noncash transaction which settled significant debt of the Company in the form of a litigation funding agreement. NovelStem was formerly known as Hollywood Media Corp. The Company was incorporated in the State of Florida on January 22, 1993 and changed its name to NovelStem International Corp. in September 2018.

 

NewStem focused on the development and commercialization of diagnostic technology that can predict patients’ anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. NewStem was liquidated in August 2025 at which time its intangible assets, primarily in the form of licensing agreements, reverted to the original license holder. The Company retains a right to income from these license agreements.

 

NetCo is a legacy media business interest which owns “Net Force”, a book publishing franchise.

 

Going Concern, Liquidity and Management’s Plans

 

Since inception, the Company has accumulated a deficit of approximately $294,000,000. The accumulated deficit of the Company subsequent to its business focus shift and name change in September 2018 is approximately $7,525,000 which is comprised primarily of allocated losses from equity method investments and general and administrative costs incurred by the Company.

 

The Company will need to obtain additional funds to continue its operations. Management’s plans with regard to these matters include additional financing and fundraising as well as monetization of the right to intangible assets held from NewStem as well as potential merger or buyout transactions. Specifically, the Company sold its interest in NetCo to its joint venture partner in a transaction that satisfied the related debt (litigation funding agreement). Also, the Company is working with former NewStem management to monetize the technology of NewStem and has an agreement in place to receive up to $3,750,000 of any monetization of these licenses and related intangible assets. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient cash from financing on terms acceptable to the Company, or that the Company will realize any value from the retained interest in intangible assets or technology of NewStem, which was liquidated in August 2025 (see Note 3).

 

The Company has in place a finance agreement with two individuals who are shareholders and directors under which it borrowed $750,000 and an additional finance agreement with a shareholder under which it borrowed $300,000 for working capital needs (see Note 4). Additionally, the Company entered into additional finance agreements with unrelated parties in December 2023 and April 2024 under which it borrowed an additional $350,000 for working capital needs and to fund NewStem (see Note 4). All funds available pursuant to these agreements have been received. During the nine months ended September 30, 2026 and the year ended December 31, 2025, the Company’s Executive Chairman advanced a cumulative net amount of approximately $140,000 to the Company as an interim bridge loan to fund ongoing expenses. The Company will need to obtain additional funds to continue operations for the next 12 months.

 

On May 9, 2025, the Company entered into a Settlement Agreement and Release whereby the investment in NetCo was monetized to settle the litigation funding liability to Omni Bridgeway in full. See Note 4.

 

On March 13, 2026, the Company received $250,000 in exchange for 2,450,980 shares of common stock from an individual accredited investor.

 

As of the date of this filing, the Company is in negotiations with all debt holders to convert their debt to equity in the Company.

 

In view of the matters described above, the Company’s ability to meet financing requirements is dependent upon the ability to complete additional fundraising or obtain additional financing, and/or monetize the rights to intangible assets from NewStem. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

 

7
 

 

NOTE 2—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary to present fairly the results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period.

 

The accompanying unaudited condensed financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed financial statements have read or have access to the audited financial statements for the preceding fiscal year. Accordingly, these unaudited condensed financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on March 26, 2026, from which the Company derived the balance sheet data at December 31, 2025.

 

Certain information and footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations for interim reporting. The Company believes that the disclosures contained herein are adequate to make the information presented not misleading. These condensed financial statements should be read in conjunction with the Company’s Form 10K, filed with the Securities and Exchange Commission on March 26, 2026, for the years ended December 31, 2025 and 2024.

 

Equity Investments

 

Investee companies that are not consolidated, but over which the Company exercises significant influence, are accounted for under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an investee depends on an evaluation of several factors, including, among others, representation on the investee company’s board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the investee company. Under the equity method of accounting, an investee company’s accounts are not reflected within the Company’s balance sheets or statements of operations; however, the Company’s share of the earnings or losses of the investee company would be reflected in the caption “Equity in net income (loss) of equity method investees” in the statements of operations. The Company’s carrying value in an equity method investee company is reflected in the caption “Investment in investee company” in the Company’s Balance Sheets.

 

The Company reviewed equity investments for impairment on an annual basis, or earlier if events or changes in circumstances indicate that the carrying amounts might not be recoverable.

 

The Company held a minority investment in an entity, NewStem, which was accounted for pursuant to the equity method of accounting. NewStem was liquidated in August 2025. See Note 3.

 

Additionally, until May 9, 2025 the Company was a 50% joint venture partner in NetCo which was accounted for pursuant to the equity method of accounting. See Note 3.

 

8
 

 

Basic and Diluted Net Income (Loss) Per Share

 

Basic net income (loss) per share is computed by dividing the net income (loss) by the weighted average number of shares outstanding during the period, excluding treasury stock. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares outstanding plus the dilutive potential of common shares which would result from the exercise of stock options and warrants or the conversion of debt. The dilutive effects of stock options and warrants are excluded from the computation of diluted net income (loss) per share if the effect of doing so would be antidilutive.

 

The following data represents the amounts used in computing earnings per share and the effect on loss and the weighted average number of shares of dilutive potential common stock (unaudited):

 

   2026   2025 
   Nine Months Ended September 30, 
   2026   2025 
Net income (loss) attributable to common shareholders  $(225,105)  $2,469,177 
           
Weighted average shares outstanding:          
-Basic   48,695,021    46,881,475 
           
Basic net income (loss) per share  $(0.00)  $0.05 
           
Net income (loss) attributable to common shareholders  $(225,105)  $2,469,177 
Effect of dilutive securities:          
Convertible debt, interest   -    6,787 
           
Net income (loss) attributable to common shareholders  $(225,105)  $2,475,964 
           
Weighted average shares outstanding:          
-Basic   48,695,021    46,881,475 
Add: Convertible Debt   -    891,485 
Add: Stock options   -    - 
-Diluted   48,695,021    47,772,960 
           
Diluted net income (loss) per share  $(0.00)  $0.05 

 

   2026   2025 
   Three Months Ended September 30, 
   2026   2025 
Net income (loss) attributable to common shareholders  $(84,289)  $(77,448)
           
Weighted average shares outstanding:          
-Basic   49,332,455    46,881,475 
           
Basic net income (loss) per share  $(0.00)  $(0.00)
           
Net income (loss) attributable to common shareholders  $(84,289)  $(77,448)
Effect of dilutive securities:          
Convertible debt, interest   -    - 
           
Net income (loss) attributable to common shareholders  $(84,289)  $(77,448)
           
Weighted average shares outstanding:          
-Basic   49,332,455    46,881,475 
Add: Convertible Debt   -    - 
Add: Stock options   -    - 
-Diluted   49,332,455    46,881,475 
           
Diluted net income (loss) per share  $(0.00)  $(0.00)

 

Options and convertible debt excluded from the computation of earnings per share (unaudited):

 

   2026   2025 
   Nine Months Ended September 30, 
   2026   2025 
Convertible debt   984,838    - 
Stock options   6,060,000    6,360,000 

 

   2026   2025 
   Three Months Ended September 30, 
   2026   2025 
Convertible debt   984,838    - 
Stock options   6,060,000    6,360,000 

 

9
 

 

NOTE 3—EQUITY METHOD INVESTMENTS

 

Investment in NewStem

 

The Company held a 31% interest in NewStem until its liquidation in August 2025.

 

The Company accounted for its investment in NewStem under the equity method. NewStem was a development stage company which incurred losses from inception and generated only minimal revenues under a licensing agreement.

 

The Company assessed its investment in NewStem for impairment on an annual basis or more frequently if indicators of impairment existed. During the year ended December 31, 2024, indicators of impairment became evident due to the inability of NewStem to raise funds. Due to the inability to raise funds, NewStem was unable to continue operations and was liquidated. The intangible assets of NewStem, including license agreements (the “License”), have reverted to the licensor, Yissum (the commercial division of Hebrew University). The Company has reached an agreement with Yissum regarding the potential monetization of these intangible assets which provides for funds to be received by the Company in the event of re-licensing or monetizing the licenses or related technology developed by NewStem. Due to the current uncertainty of the recovery of any value from these intangible assets and the liquidation status of NewStem, the Company fully impaired the investment in NewStem during the year ended December 31, 2024. On August 14, 2025, the Company received $5,432 from NewStem upon the final closing of their accounts and in October 2025, the Company wrote off all asset accounts and the related impairment and ceased accounting for NewStem.

 

Investment in NetCo

 

Until May 2025, NovelStem owned a 50% interest in NetCo, a joint venture that owns the Net Force publishing franchise. On May 9, 2025, the Company entered into a Settlement Agreement and Release whereby the investment in NetCo was sold to the Company’s JV partner, C. P. Group, Inc. (“CP Group”), for $1,300,000 to settle the related litigation funding liability to Omni Bridgeway in full. This transaction was fully consummated as funds were received by Omni Bridgeway from CP Group pursuant to the terms of the agreement.

 

The following table represents the Company’s investment in NetCo:

 

  

Nine Months Ended

September 30, 2026

  

Year Ended

December 31, 2025

 
    (Unaudited)      
Investment in NetCo, beginning  $-   $128,240 
Allocation of net income (loss) from NetCo   -    640 
Distribution from NetCo   -    (640)
Sale of ownership interest in NetCo   -    (128,240)
Investment in NetCo, ending  $-   $- 

 

The results of operations of the Company’s investment in NetCo is summarized below (unaudited): 

 

   2026   2025   2026   2025 
   Nine Months Ended September 30,   Three Months Ended September 30, 
   2026   2025   2026   2025 
Condensed income statement information:                    
Net sales  $-   $-   $-   $- 
Gross margin  $-   $(79)  $-   $- 
Net income  $-   $680   $-   $- 
Company’s allocation of net income from NetCo  $-   $340   $-   $- 

 

10
 

 

NOTE 4—NOTES PAYABLE

 

In December 2023, the Company entered into two notes payable with unrelated parties, Hewlett Fund and AIGH Investment Partners, LLC. The notes are for $125,000 each, for a total of $250,000 in borrowings utilized for the funding of NewStem. The notes bear interest at 12% per annum prior to an event of default and at 24% per annum following an event of default and originally matured on December 21, 2024. The maturity date of both notes has been extended by successive loan extension agreements entered into with each holder on March 25, 2025, February 17, 2026 and August 3, 2026, most recently to March 30, 2027, at which time all principal and accrued interest are due and payable. Each extension agreement provides that all other terms and conditions of the notes remain in full force and effect.

 

The notes provide that principal and accrued interest become due and payable upon the earlier of the stated maturity date or the closing of a capital raise, which the notes define as any transaction, whether debt, equity or any combination thereof, to raise capital for the Company. The notes further provide that, in the event of a capital raise, each holder is entitled to participate in that transaction and to tender its note, valued at 133% of the amounts owed under the note on the closing date of the transaction, as payment for any securities issued to that holder in the transaction.

 

The Company completed a capital raise on March 13, 2026 through the issuance of common stock for cash proceeds of $250,000 (see Note 5) and has entered into other financing transactions since the notes were issued. Neither holder elected to participate in, or tendered its note in connection with, any such transaction, and neither holder demanded repayment nor accelerated its note. The Company has accrued interest on the notes at 12% per annum in all periods presented. In August 2026, the Company entered into waiver and confirmation agreements with both holders under which each holder confirmed the amount owed under its note as of June 30, 2026; confirmed that interest has accrued and continues to accrue at 12% per annum and that no interest is or will become payable at the 24% default rate specified in the notes in respect of any period through the date of the agreements; confirmed the maturity date of March 30, 2027; and waived any right it may have had, arising from any financing transaction completed on or prior to the date of those agreements, to accelerate its note, to participate in or tender its note, or to assert an event of default. All other terms of the notes remain unchanged, including the provisions relating to future capital raise transactions, which the agreements made subject to a notice and election procedure. Accordingly, no interest has been accrued at the default rate in any period presented, and no liability has been recorded in respect of these provisions.

 

Interest expense related to these notes was $29,463 and $27,575, respectively, for the nine months ended September 30, 2026 and 2025. Interest expense related to these notes was $10,113 and $8,985, respectively, for the three months ended September 30, 2026 and 2025.

 

In May 2022, the Company entered into note agreements with Jan Loeb, our Executive Chairman and Jerry Wolasky, a shareholder and member of the Board, to borrow up to an aggregate of $600,000 for working capital needs. The note agreements were amended in March 2024 to increase the total borrowing to $650,000 and extend the maturity date. The note agreements were refinanced in August 2024 providing for total borrowings of $750,000. The agreements provide for interest at a rate of 10% per annum and matured December 31, 2025. As of the date of these financial statements, the full amount of $750,000 has been funded pursuant to these agreements. The maturity dates were previously extended to June 30, 2026 and, pursuant to loan extension agreements dated August 3, 2026, were further extended to March 30, 2027. All other terms of the notes, including the interest rate, remain unchanged. Interest expense related to these agreements was $73,747 and $67,432 for the nine months ended September 30, 2026 and 2025, respectively. Interest expense related to these agreements was $25,197 and $24,659 for the three months ended September 30, 2026 and 2025, respectively.

 

The Company has in place a note payable with a shareholder for $336,000. The note bore no interest and included a guarantee which was identified as an embedded derivative. This note agreement was amended in May 2025 to provide for a fixed amount of interest of $36,000 in lieu of the guarantee. This interest was added to note principal. This amendment, which was determined to be accounted for pursuant to the provisions of ASC 470 for troubled debt restructurings with related parties, ended the discounting of the note from the zero interest rate and the separate recording of an embedded derivative, as the note now bears interest and contains no identifiable embedded derivative. As such, the relief of the guarantee was recorded as an adjustment to equity and interest expense of $36,000 was accrued and treated as a reduction to equity. Beginning October 1, 2025, the note began to bear interest at a rate of 10% per annum. The note matures on December 31, 2026. Interest expense related to this note was $26,711 and $9,126, respectively, for the nine and three months ended September 30, 2026.

 

Note Payable Litigation Funding Agreement

 

On February 11, 2022, the Company entered into a nonrecourse litigation funding agreement (the “Agreement”) with Omni Bridgeway (Fund 4) Invt. 3 L.P. (“Omni”) related to an arbitration proceeding that was subsequently settled in July 2023. The Agreement provided for Omni to fund all costs related to the arbitration up to $1,000,000 in exchange for an assignment of a certain portion of rights to and interest in claims related to this arbitration. The agreement provided for specific calculations of the portion of any claims collected to be received by Omni with the remainder collectible by the Company. Additionally, the agreement provided for repayment of funded costs pursuant to the same multiple calculations in the event of a favorable outcome that does not include the collection of claims.

 

11
 

 

During July 2023, the arbitration was settled. As a result of the ruling, the liability became probable and reasonably estimable, and the Company recorded the full liability due to Omni as of December 31, 2023. This liability consisted of expenses funded by Omni of $933,065, including $310,000 advanced for working capital, and related fees or investment return to Omni calculated as contractual multiples of funding totaling $1,886,131 for a total liability at inception of $2,819,196. This agreement bore interest at 5% per annum beginning January 2024 and was payable in full on January 10, 2025. Prior to settlement of the Agreement, the Company accrued interest of $37,400 during the nine months ended September 30, 2025.

 

The Company began negotiations for settlement of this Agreement during 2024 and on May 9, 2025, the Company entered into a Settlement Agreement and Release with our JV partner in NetCo, C. P. Group, and Omni whereby our interest in NetCo was sold in exchange for funds of $1,300,000 which were paid directly to Omni by CP Group in full settlement and release of all liabilities related to the Litigation Funding Agreement. This resulted in the noncash settlement in full of $2,997,025 including accrued and unpaid interest.

 

Bridge Loan

 

In February 2025, Jan Loeb, Executive Chairman, began advancing funds to the Company for operating expenses in the form of an interim bridge loan until alternate funding sources can be found. The bridge loan matured on December 31, 2025 and was previously extended to June 30, 2026. Pursuant to a loan extension agreement dated August 3, 2026, the maturity was further extended to March 30, 2027. The Company is accruing interest at 10% per annum for these advances. The net principal balance outstanding at September 30, 2026 is $140,115. The total advanced during the nine months ended September 30, 2026 was $28,248, and no advances were made during the three months ended September 30, 2026. Additionally, $50,000 was repaid during the nine months ended September 30, 2026. The total advanced during the year ended December 31, 2025 was $161,867. Interest expense related to these advances was $12,166 and $3,990, respectively, during the nine and three months ended September 30, 2026. Interest expense related to these advances was $5,984 and $4,532, respectively, during the nine and three months ended September 30, 2025.

 

Convertible Debt

 

In April 2024, the Company borrowed $100,000 from unrelated parties pursuant to convertible debt agreements accounted for as debt. These agreements bear interest at 10% per annum and matured on December 30, 2025. In August 2026, the maturity dates were extended to March 30, 2027. The unpaid principal balance of these notes and any accrued interest may be converted into shares of the Company’s common stock at a conversion price of $0.13 per share. Interest accrued related to these agreements was $9,214 and $8,321, respectively, during the nine months ended September 30, 2026 and 2025. Interest accrued related to these agreements was $3,148 and $2,850, respectively, during the three months ended September 30, 2026 and 2025.

 

The Company evaluated each extension under ASC 470-50 and ASC 470-60 and accounted for them as modifications of the existing debt; no gain or loss was recognized.

 

Notes payable are summarized as follows:

 

   As of 
   September 30,   December 31, 
   2026   2025 
   (Unaudited)     
Notes payable, unrelated parties (Hewlett Fund and AIGH Investment Partners, LLC):          
Notes payable, principal amount  $250,000   $250,000 
Accrued interest added to note balance   97,196    67,734 
Total notes payable, unrelated parties   347,196    317,734 
Notes payable related parties:          
Notes payable director and Executive Chairman   821,766    821,766 
Accrued interest added to note balance   202,955    129,208 
Total notes payable director and Executive Chairman   1,024,721    950,974 
Note payable shareholder, principal amount   336,000    336,000 
Accrued interest added to note balance   35,142    8,431 
Total note payable shareholder   371,142    344,431 
Total notes payable related parties   1,395,863    1,295,405 
Bridge loan payable, related party:          
Net principal advances   140,115    161,867 
Accrued interest added to loan balance   22,156    9,990 
Total bridge loan payable, related party   162,271    171,857 
Convertible debt:          
Convertible notes, principal amount   100,000    100,000 
Accrued interest added to note balance   28,029    18,814 
Total convertible debt   128,029    118,814 
Total notes payable  $2,033,359   $1,903,810 

 

The notes payable summarized above were originally issued with maturities greater than one year. Since their original maturity dates, the notes have been extended from time to time, in each case for a period of less than one year from the date of extension. Accordingly, all amounts are due within one year of each balance sheet date presented and are classified as current liabilities, and no amounts have been classified as long-term.

 

The weighted average interest rate on the Company’s notes payable, all of which are classified as current, was approximately 10.3% at September 30, 2026 and December 31, 2025.

 

NOTE 5—EQUITY

 

(a) General

 

At September 30, 2026, the Company had issued 52,767,652 shares and had 49,332,455 shares of its stock outstanding with a par value of $0.01 per share.

 

At December 31, 2025, the Company had issued 50,316,672 shares and had 46,881,475 shares of its common stock outstanding with a par value of $0.01 per share.

 

In March 2026, the Company issued 2,450,980 shares of its common stock to an individual accredited investor in a privately negotiated transaction for cash proceeds of $250,000, or $0.102 per share. The proceeds were recorded as $24,510 of common stock at par value and $225,490 of additional paid-in capital and were used for working capital and general corporate purposes. The shares issued rank equally with, and carry the same rights and privileges as all other outstanding shares of the Company’s common stock. No warrants, options, registration rights, board designation rights, anti-dilution or price protection, or similar rights were granted in connection with the transaction, and the purchaser holds less than 5% of the Company’s outstanding common stock. The shares were not registered under the Securities Act of 1933 and were issued in reliance on the exemption from registration provided by Section 4(a)(2) thereof and Rule 506(b) of Regulation D promulgated thereunder.

 

Holders of outstanding common stock are entitled to receive dividends when, and if declared by the Board, and to share ratably in the assets of the Company legally available for distribution in the event of liquidation, dissolution or winding up of the Company.

 

12
 

 

(b) Summary Employee Option Information

 

The Company’s stock option plan provides for the grant to officers, directors, third party contractors and other future key employees of options to purchase shares of common stock. The purchase price may be paid in cash or, if the option is “in-the-money”, it is automatically exercised “net”. In a net exercise of an option, the Company does not require a payment of the exercise price of the option from the optionee but reduces the number of shares of common stock issued upon the exercise of the option by the smallest number of whole shares that has an aggregate fair market value equal to or in excess of the aggregate exercise price for the option shares covered by the option exercised. Each option is exercisable to one share of the Company’s common stock. Most options expire within six years from the date of the grant and generally vest on the first anniversary date of their issuance. Pursuant to the Equity Incentive Plan the Company’s board of directors approved on November 12, 2018, an aggregate of 6,360,000 options have been issued to directors and investor relations professionals of which 300,000 have expired and 6,060,000 remain outstanding.

 

No options were issued during the nine months ended September 30, 2026 and 2025.

 

The expected term of the options represents an estimate of the length of time until the expected date of exercising the options. Options granted have a maximum life of 7 years. With respect to determining expected exercise behavior, the Company has grouped its option grants into certain groups to track exercise behavior and establish historical rates. The Company estimated volatility by considering historical stock volatility over the expected term of the option. The risk-free interest rates are based on the U.S. Treasury yields for a period consistent with the expected term. The dividend yield of 0% is based on the Company’s history and expectation of dividend payout. The Company has not paid and does not anticipate paying dividends in the near future.

 

(c) Summary Option Information

 

A summary of the Company’s option plans for the nine months ended September 30, 2026, is presented below (unaudited):

 

   Number   Weighted 
   of Options   Average 
   (in shares)   Exercise Price 
Outstanding, December 31, 2025   6,060,000   $0.137 
Granted   -    - 
Outstanding, September 30, 2026   6,060,000   $0.137 
Exercisable, September 30, 2026   6,060,000   $0.137 

 

Stock-based compensation expense was $8,838 and $0 in the nine and three months ended September 30, 2025, respectively. There was no such stock-based compensation expense during the nine and three months ended September 30, 2026. Options to purchase 300,000 shares of common stock expire on November 26, 2026.

 

(d) Warrants

 

The Company had issued warrants at exercise prices equal to or greater than the market value of the Company’s common stock at the date of issuance. All warrants expired on June 28, 2025.

 

13
 

 

NOTE 6—INCOME TAXES

 

The Company’s income tax expense and effective tax rates for the nine and three months ended September 30, 2026 and 2025 were as follows:

 

   2026   2025   2026   2025 
  

Nine Months Ended

September 30,

  

Three Months Ended

September 30,

 
   2026   2025   2026   2025 
Income (loss) before income taxes  $(225,105)   2,463,105   $(84,289)  $(83,180)
Income tax expense   -    -    -    - 
Effective tax rate   0.00%   0.00%   0.00%   0.00%

 

The Company’s income tax provision differs from the expense that would result from applying statutory rates to income (loss) before taxes. A reconciliation of the provision (benefit) for income taxes with amounts determined by applying the statutory U.S. federal income tax rate to income before income taxes is as follows (unaudited):

 

   Amount   Tax Rate   Amount   Tax Rate 
   Nine Months Ended September 30, 
   2026   2025 
   Amount   Tax Rate   Amount   Tax Rate 
Computed tax at the federal statutory rate of 21%  $(47,272)   21.00%  $517,252    21.00%
Increase (decrease) in income tax rate resulting from:                    
State income taxes, net of federal income tax benefit   (9,781)   4.35%   107,145    4.35%
Permanent difference - relief of indebtedness income   -    0.00%   (356,375)   (14.47)%
Prior-year return-to-provision and §108(b) attribute adjustments   111,561    (49.56)%   -    0.00%
Change in measurement of state deferred taxes (net of federal income tax benefit)   861,719    (382.81)%   -    0.00%
Change in valuation allowance   (916,227)   407.02%   (268,022)   (10.88)%
Total provision for income tax  $-    0.00%  $-    0.00%

 

   Amount   Tax Rate   Amount   Tax Rate 
   Three Months Ended September 30, 
   2026   2025 
   Amount   Tax Rate   Amount   Tax Rate 
Computed tax at the federal statutory rate of 21%  $(17,701)   21.00%  $(17,468)   21.00%
Increase (decrease) in income tax rate resulting from:                    
State income taxes, net of federal income tax benefit   (3,662)   4.34%   (3,618)   4.35%
Permanent difference - relief of indebtedness income   -    0.00%   -    0.00%
Prior-year return-to-provision and §108(b) attribute adjustments   111,561    (132.36)%   -    0.00%
Change in measurement of state deferred taxes (net of federal income tax benefit)   861,719    (1,022.34)%   -    0.00%
Change in valuation allowance   (951,917)   1,129.36%   21,086    (25.35)%
Total provision for income tax  $-    0.00%  $-    0.00%

 

State income taxes are presented net of the federal income tax benefit.

 

During the three months ended September 30, 2026, the Company changed the measurement of its state deferred tax assets to reflect the federal income tax effect of state income taxes, using a combined federal and state rate of 25.345% (previously 26.5%). Remeasuring the deferred tax assets that existed at December 31, 2025 reduced gross deferred tax assets and the related valuation allowance by $861,719. As of September 30, 2026, gross deferred tax assets and the valuation allowance are $856,691 lower than under the previous measurement. Because the Company maintains a full valuation allowance against its net deferred tax assets, the change had no effect on the Company’s income tax provision, effective tax rate, financial position, results of operations or cash flows. Amounts as of December 31, 2025 have not been revised. In addition, during the three months ended September 30, 2026, the Company recorded adjustments of $111,561 to its deferred tax assets to true up the 2025 provision to the Company’s 2025 federal and state income tax returns and amended 2024 returns, including the reduction of tax attributes required by Section 108(b) of the Internal Revenue Code as a result of the 2025 relief of indebtedness income. These adjustments were fully offset by the valuation allowance and had no effect on the Company’s income tax provision.

 

NOTE 7—COMMITMENTS AND CONTINGENCIES

 

In July 2026, the Company entered into a contractual obligation related to our directors’ and officers’ insurance providing for a down payment of $8,690 followed by 10 monthly installments of $3,436 beginning in September 2026. As of September 30, 2026, the remaining payments under this agreement totaled $30,925.

 

NOTE 8—SUBSEQUENT EVENTS

 

The Company evaluated subsequent events through the date these financial statements were available to be issued and filed with the SEC.

 

There were no subsequent events requiring recognition or disclosure in these financial statements.

 

14
 

 

NOVELSTEM INTERNATIONAL CORP.

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Statements in the following discussion and throughout this Form 10-Q that are not historical in nature are “forward-looking statements.” You can identify forward-looking statements by the use of words such as “expect,” “anticipate,” “estimate,” “may,” “will,” “should,” “intend,” “believe,” and similar expressions. Although we believe the expectations reflected in these forward-looking statements are reasonable, such statements are inherently subject to risk and we can give no assurances that our expectations will prove to be correct. Actual results could differ from those described in this Form 10-Q because of numerous factors, many of which are beyond our control. We undertake no obligation to update these forward-looking statements to reflect events or circumstances after the date of this Form 10-Q or to reflect actual outcomes.

 

Overview

 

We are a holding company with limited operations and reported net income (losses) of approximately $(225,000) and $2,469,000 for the nine months ended September 30, 2026 and 2025, respectively, and $(84,000) and $(77,000), for the three months ended September 30, 2026 and 2025, respectively. We had current assets of approximately $32,000 and current liabilities of $2,149,000 as of September 30, 2026. As of December 31, 2025, our current assets and current liabilities were approximately $16,000 and $2,157,000, respectively. The increase in current assets is due to the sale of equity securities during the nine months ended September 30, 2026. The decrease in current liabilities is primarily due to the reduction of accounts payable and the repayment of $50,000 on short-term borrowings as offset by interest accrued on debt and advances on short-term borrowings to fund operating expenses.

 

We have prepared our financial statements for the nine months ended September 30, 2026, assuming that we will continue as a going concern. Our continuation as a going concern is dependent upon improving our profitability and the continuing financial support from our shareholders as well as Yissum’s ability to successfully commercialize the License. Our sources of capital in the past have included the sale of equity securities, which include common stock sold in private transactions, and related party debt as well as debt from unrelated parties. During 2025 we entered into a bridge loan agreement with our Executive Chairman to obtain funding for current operating expenses and in March 2026 we issued common stock in exchange for $250,000 in a private transaction.

 

RESULTS OF OPERATIONS

 

The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes thereto and other financial information appearing elsewhere in this Form 10-Q. In the discussion below, general and administrative expenses are referred to as “G&A expenses”.

 

  

Nine Months Ended September 30,

   Three Months Ended September 30, 
   2026   2025   Change   2026   2025   Change 
                         
Operating expenses:                              
General and administrative expenses   72,455    198,007    (125,552)   32,567    39,469    (6,902)
Total operating expenses   72,455    198,007    (125,552)   32,567    39,469    (6,902)
Loss from operations   (72,455)   (198,007)   125,552    (32,567)   (39,469)   6,902 
Other (income) expenses:                              
Gain on disposal of equity method investment   -    (1,171,760)   1,171,760    -    -    - 
Relief of indebtedness income   -    (1,697,024)   1,697,024    -    -    - 
Interest expense   152,650    207,672    (55,022)   51,722    43,711    8,011 
Total other (income) expenses   152,650    (2,661,112)   2,813,762    51,722    43,711    8,011 
Income (loss) before income taxes   (225,105)   2,463,105    (2,688,210)   (84,289)   (83,180)   (1,109)
Provision for income tax   -    -    -    -    -    - 
Income (loss) before equity in net income (loss) of equity method investees   (225,105)   2,463,105    (2,688,210)   (84,289)   (83,180)   (1,109)
Equity in net income (loss) of equity method investees   -    640    (640)   -    300    (300)
Impairment of equity method investee, NewStem   -    5,432    (5,432)   -    5,432    (5,432)
Net income (loss)   (225,105)   2,469,177    (2,694,282)  $(84,289)  $(77,448)  $(6,841)

 

We are a holding company whose primary asset currently is our right to the monetization of the former NewStem license now held by Yissum. We currently conduct no other business and as a result, we have no operating revenue or cost of revenue.

 

The Company incurs general and administrative (“G&A”) expenses primarily related to professional fees, insurance and stock-based compensation. We incurred G&A expenses of approximately $72,000 and $198,000 for the nine months ended September 30, 2026 and 2025, respectively. Specifically, professional fees decreased by approximately $90,000 in the nine months ended September 30, 2026 as compared to the nine months ended September 30, 2025, primarily due to a decrease in audit fees of approximately $25,000 and the write off of approximately $67,500 in prior years legal fees due to the settlement of outstanding fees at a discount. We incurred a bad debt expense during the nine months ended September 30, 2025 of approximately $9,500 for the write off of uncollectible administrative fees. We had reductions in stock compensation of approximately $8,800 as previously issued stock options were fully expensed during 2025, and reductions in transfer agent and other stock-related fees of approximately $8,900. Insurance expense and investor relations costs decreased by approximately $4,700 and $3,500, respectively, primarily due to a lower premium on the renewal of our directors’ and officers’ insurance policy and lower filing agent costs.

 

We incurred G&A expenses of approximately $33,000 and $39,000 for the three months ended September 30, 2026 and 2025, respectively. The decrease is primarily due to lower insurance expense of approximately $4,800 resulting from a lower premium on the renewal of our directors’ and officers’ insurance policy and lower investor relations costs of approximately $1,900. Other G&A expenses were comparable between the periods.

 

15
 

 

Interest expense decreased by approximately $55,000 in the nine months ended September 30, 2026 as compared to the nine months ended September 30, 2025, primarily due to the settlement of the litigation funding agreement on May 9, 2025, on which interest of $37,400 was accrued in 2025, and accretion of discount on the shareholder note payable of approximately $60,000 in 2025, partially offset by interest on the shareholder note, which began to bear interest at 10% per annum on October 1, 2025, and higher interest on the bridge loan and other notes as accrued interest is added to note balances. Interest expense increased by approximately $8,000 in the three months ended September 30, 2026 as compared to the three months ended September 30, 2025, primarily due to interest of approximately $9,000 on the shareholder note.

 

The Company has recorded no income tax expense as we have incurred operating losses and all deferred tax assets are fully offset by an income tax valuation allowance.

 

We reported net income from equity method investees during the nine and three months ended September 30, 2025 which consisted of income from NetCo of $640 and $300, respectively, and a recovery of impairment expense of $5,432 related to cash received in the liquidation of NewStem in the nine and three months ended September 30, 2025. We had no equity method investees during 2026.

 

Liquidity and Capital Resources

 

We have not paid dividends on our common stock since our name change and business focus shift in 2018. Our present policy is to apply cash to debt service, acquisitions or expansion; consequently, we do not expect to pay dividends on common stock in the foreseeable future.

 

The Company will need to obtain additional funds to continue its operations. Management’s plans with regard to these matters include fundraising until our interest in NewStem’s technology via monetization of the License is profitable. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient cash from financing on terms acceptable to the Company, or that NewStem’s technology will be monetized and become profitable.

 

The Company has in place note agreements entered into during 2022 with Jan Loeb, our Executive Chairman and Jerry Wolasky, a member of the Board, to borrow up to an aggregate of $750,000 for working capital needs. The agreements provide for interest at a rate of 10% per annum and mature March 30, 2027. As of the date of this Quarterly Report, the full amount of $750,000 has been funded pursuant to these agreements.

 

During the year ended December 31, 2023, the Company entered into a note agreement with a shareholder to borrow $300,000 for continued working capital. This note bore interest at zero percent (0%) and matured on May 5, 2025. The note included a guarantee which was identified as an embedded derivative. This note was amended in May 2025 to provide for fixed interest from inception of $36,000 to be added to the principal balance, remove the guarantee and extend the maturity date to September 30, 2025. This note was amended for a second time in October 2025 to extend the maturity date to December 31, 2026.

 

In December 2023, the Company entered into two notes payable with unrelated parties for a total of $250,000 in borrowings utilized for the funding of NewStem. The notes bear interest at 12% per annum prior to an event of default and mature March 30, 2027, at which time all principal and accrued interest are due and payable. The notes provide that principal and accrued interest become due and payable upon the earlier of the stated maturity date or the closing of a capital raise, and that in the event of a capital raise each holder is entitled to participate in that transaction and to tender its note, valued at 133% of the amounts owed on the closing date, as payment for securities issued to that holder. In August 2026, the Company entered into waiver and confirmation agreements with both holders with respect to financing transactions completed on or prior to the date of those agreements, including the March 13, 2026 issuance of common stock.

 

In April 2024, the Company borrowed $100,000 from unrelated parties pursuant to convertible debt agreements accounted for as debt. The notes bear interest at 10% per annum and mature March 30, 2027.

 

In February 2025, the Company entered into a bridge loan agreement with the Executive Chairman to fund working capital until such time as additional funding can be obtained. Advances from this note were approximately $28,000 and $136,000 during the nine months ended September 30, 2026 and 2025, respectively. The Company repaid $50,000 on this note during the nine months ended September 30, 2026. The note bears interest at 10% per annum and matures March 30, 2027.

 

On May 9, 2025 the Company sold its interest in NetCo to its JV partner for $1,300,000 which was paid directly to Omni Bridgeway in full settlement of all liabilities related to the litigation funding agreement totaling $2,959,625 including all accrued and unpaid interest.

 

On March 13, 2026, the Company received $250,000 in exchange for 2,450,980 shares of common stock from an unrelated party.

 

16
 

 

Net Cash Used In Operating Activities.

 

For the nine months ended September 30, 2026, net cash used in operating activities was approximately $206,000, which consisted primarily of a net loss of approximately $225,000 and the noncash settlement of accounts payable of $67,500, offset by interest added to notes payable of approximately $151,000. Additionally, cash was used in operations related to a decrease in accounts payable of approximately $71,000, offset by a decrease in prepaid expenses of approximately $6,000.

 

For the nine months ended September 30, 2025, net cash used in operating activities was approximately $141,000, which consisted primarily of net income of approximately $2,469,000, offset by noncash disposal of equity method investment of approximately $1,172,000, relief of indebtedness income of approximately $1,697,000, stock-based compensation of approximately $9,000, accretion of discount on notes payable of approximately $60,000 and interest added to notes payable of approximately $146,000. Additionally, cash was provided by operations related to a decrease in current assets of approximately $12,000 and a net increase in accounts payable of approximately $32,000.

 

Net Cash Used In Investing Activities.

 

No net cash was used in investing activities during the nine months ended September 30, 2026 and 2025.

 

Net Cash Provided By Financing Activities.

 

For the nine months ended September 30, 2026, net cash provided by financing activities was approximately $228,000, consisting of short-term borrowings from the Executive Chairman of approximately $28,000 and proceeds from the issuance of common stock of $250,000, offset by repayment of $50,000 in short-term borrowings from the Executive Chairman.

 

For the nine months ended September 30, 2025, net cash provided by financing activities was approximately $136,000, consisting of short-term borrowings from the Executive Chairman.

 

17
 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

 

This section is not applicable.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Our Principal Executive Officer and Chief Financial Officer conducted an evaluation of our controls and procedures. We have identified material weaknesses in our internal control and procedures and internal control over financial reporting. If not remediated, our failure to establish and maintain effective disclosure controls and procedures and internal control over financial reporting could result in material misstatements in our financial statements and a failure to meet our reporting and financial obligations, each of which could have a material adverse effect on our financial condition and the trading price of our common stock.

 

Maintaining effective internal control over financial reporting and effective disclosure controls and procedures are necessary for us to produce reliable financial statements. We have re-evaluated our internal control over financial reporting and our disclosure controls and procedures and concluded that they were not effective as of September 30, 2026 and we concluded there was a material weakness in the design of our internal control over financial reporting as it relates to insufficient resources to employ proper segregation of duties over the processing of transactions and financial reporting.

 

A material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

 

Changes in Internal Control Over Financial Reporting

 

There was no change in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

18
 

 

PART II

 

ITEM 1. LEGAL PROCEEDINGS

 

The Company had no legal proceedings during the reporting period.

 

ITEM 1A. RISK FACTORS

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

  (a) Not applicable.
     
  (b) Not applicable.
     
  (c) Not applicable.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

Not applicable.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

None.

 

ITEM 6. EXHIBITS

 

#31.1   Certification of Principal Executive Officer and Executive Chairman pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
#31.2   Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
#32.1   Certification of Principal Executive Officer and Executive Chairman pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
#32.2   Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

# This exhibit is filed or furnished herewith.

 

19
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  NOVELSTEM INTERNATIONAL CORP.
     
Date: November 16, 2026 By: /s/ Jan Loeb
  Name: Jan Loeb
  Title: Executive Chairman
     
  By: /s/ Christine T. Jenkins
  Name: Christine T. Jenkins
  Title: Chief Financial Officer

 

20

 

Keep reading